Panorama Medicine, a Philadelphia, PA-based genomics and computing powered drug discovery company focusing on RNA therapeutics, raised $3.7m in seed funding.
The round was led by WI Harper Group and a number of other venture capital firms.
The company will use the proceeds from the financing to expand its scientific team, continue to advance its screening and big data discovery platform, and continue drug development efforts.
Launched in 2018 by Dr. Yi Xing, Dr. Douglas Black, and Mingfu Zhu, CEO, Panorama leverages core technologies licensed from academic partners to provide a screening platform and associated core technologies to find drugs that can treat diseases caused by errors during RNA processing.
The company recently addedDr. Beverly Davidson, Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Chief Scientific Strategy Officer of CHOP, to its Scientific Advisory Board. Dr. Davidson is the Vice President-elect of the Board of Directors for the American Society of Gene and Cell Therapy. She is a scientific co-founder of Spark Therapeutics and Talee Bio, and serves on the Scientific Advisory Boards of Sarepta Therapeutics, Homology Medicines, Intellia Therapeutics, and Prevail Therapeutics.